{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T02:22:18Z","timestamp":1782094938472,"version":"3.54.5"},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1016\/j.semcancer.2008.09.001","type":"journal-article","created":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T09:46:12Z","timestamp":1222854372000},"page":"409-415","source":"Crossref","is-referenced-by-count":11,"title":["Contribution of viral recombinants to the study of the immune response against the Epstein-Barr virus"],"prefix":"10.1016","volume":"18","author":[{"given":"Henri-Jacques","family":"Delecluse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Feederle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Behrends","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Mautner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2008.09.001_bib1","series-title":"Fields virology","first-page":"655","article-title":"Epstein-Barr virus and its replication","author":"Kieff","year":"2007"},{"key":"10.1016\/j.semcancer.2008.09.001_bib2","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.1073\/pnas.96.9.5188","article-title":"A first-generation packaging cell line for Epstein-Barr virus-derived vectors","volume":"96","author":"Delecluse","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.semcancer.2008.09.001_bib3","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S0076-6879(99)06020-6","article-title":"Applications of oriP plasmids and their mode of replication","volume":"306","author":"Mackey","year":"1999","journal-title":"Methods Enzymol"},{"key":"10.1016\/j.semcancer.2008.09.001_bib4","first-page":"532","article-title":"Herpesvirus vectors come of age","volume":"2","author":"Hammerschmidt","year":"2000","journal-title":"Curr Opin Mol Ther"},{"key":"10.1016\/j.semcancer.2008.09.001_bib5","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1099\/0022-1317-77-2-227","article-title":"Epstein-Barr virus nuclear antigen 2 (EBNA2)-oestrogen receptor fusion proteins complement the EBNA2-deficient Epstein-Barr virus strain P3HR1 in transformation of primary B cells but suppress growth of human B cell lymphoma lines","volume":"77","author":"Kempkes","year":"1996","journal-title":"J Gen Virol"},{"key":"10.1016\/j.semcancer.2008.09.001_bib6","doi-asserted-by":"crossref","first-page":"8217","DOI":"10.1128\/JVI.68.12.8217-8222.1994","article-title":"Optimal lengths for DNAs encapsidated by Epstein-Barr virus","volume":"68","author":"Bloss","year":"1994","journal-title":"J Virol"},{"key":"10.1016\/j.semcancer.2008.09.001_bib7","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1128\/JVI.69.1.231-238.1995","article-title":"Immortalization of human B lymphocytes by a plasmid containing 71 kilobase pairs of Epstein-Barr virus DNA","volume":"69","author":"Kempkes","year":"1995","journal-title":"J Virol"},{"key":"10.1016\/j.semcancer.2008.09.001_bib8","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1126\/science.2660262","article-title":"Construction of large DNA segments in Escherichia coli","volume":"244","author":"O\u2019Connor","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2008.09.001_bib9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/285333a0","article-title":"Construction in vitro and rescue of a thymidine kinase-deficient deletion mutation of herpes simplex virus","volume":"285","author":"Smiley","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2008.09.001_bib10","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0092-8674(80)90172-5","article-title":"Molecular engineering of the herpes simplex virus genome: insertion of a second L\u2013S junction into the genome causes additional genome inversions","volume":"22","author":"Mocarski","year":"1980","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2008.09.001_bib11","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0092-8674(81)90247-6","article-title":"A generalized technique for deletion of specific genes in large genomes: alpha gene 22 of herpes simplex virus 1 is not essential for growth","volume":"25","author":"Post","year":"1981","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2008.09.001_bib12","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/340393a0","article-title":"Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes","volume":"340","author":"Hammerschmidt","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2008.09.001_bib13","doi-asserted-by":"crossref","first-page":"9558","DOI":"10.1073\/pnas.86.23.9558","article-title":"Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation","volume":"86","author":"Cohen","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.semcancer.2008.09.001_bib14","doi-asserted-by":"crossref","first-page":"7298","DOI":"10.1128\/JVI.67.12.7298-7306.1993","article-title":"Epstein-Barr virus recombinants from overlapping cosmid fragments","volume":"67","author":"Tomkinson","year":"1993","journal-title":"J Virol"},{"key":"10.1016\/j.semcancer.2008.09.001_bib15","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1006\/scbi.2001.0407","article-title":"Identification of EBV transforming genes by recombinant EBV technology","volume":"11","author":"Izumi","year":"2001","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.semcancer.2008.09.001_bib16","first-page":"353","article-title":"Molecular genetics of DNA viruses: recombinant virus technology","volume":"292","author":"Neuhierl","year":"2005","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.semcancer.2008.09.001_bib17","series-title":"Fields virology","first-page":"2655","article-title":"Epstein-Barr virus","author":"Rickinson","year":"2007"},{"key":"10.1016\/j.semcancer.2008.09.001_bib18","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1182\/blood.V100.5.1755.h81702001755_1755_1764","article-title":"B cells immortalized by a mini-Epstein-Barr virus encoding a foreign antigen efficiently reactivate specific cytotoxic T cells","volume":"100","author":"Moosmann","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2008.09.001_bib19","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/eji.200425936","article-title":"Selection of CMV-specific CD8+ and CD4+ T cells by mini-EBV-transformed B cell lines","volume":"35","author":"Wiesner","year":"2005","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.semcancer.2008.09.001_bib20","doi-asserted-by":"crossref","first-page":"10357","DOI":"10.1128\/JVI.01193-06","article-title":"Identification of major histocompatibility complex class II-restricted antigens and epitopes of the Epstein-Barr virus by a novel bacterial expression cloning approach","volume":"80","author":"Milosevic","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.semcancer.2008.09.001_bib21","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1084\/jem.20051287","article-title":"Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins","volume":"203","author":"Adhikary","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.semcancer.2008.09.001_bib22","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1371\/journal.pone.0000583","article-title":"Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy","volume":"2","author":"Adhikary","year":"2007","journal-title":"PLoS ONE"},{"key":"10.1016\/j.semcancer.2008.09.001_bib23","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1093\/emboj\/19.12.3080","article-title":"The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators","volume":"19","author":"Feederle","year":"2000","journal-title":"EMBO J"},{"key":"10.1016\/j.semcancer.2008.09.001_bib24","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1182\/blood-2003-03-0930","article-title":"Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1","volume":"103","author":"Landais","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2008.09.001_bib25","doi-asserted-by":"crossref","first-page":"7939","DOI":"10.4049\/jimmunol.175.12.7939","article-title":"Long-term MHC class II presentation of the EBV lytic protein BHRF1 by EBV latently infected B cells following capture of BHRF1 antigen","volume":"175","author":"Landais","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.semcancer.2008.09.001_bib26","doi-asserted-by":"crossref","first-page":"9435","DOI":"10.1128\/JVI.00473-06","article-title":"Epstein-Barr virus BNRF1 protein allows efficient transfer from the endosomal compartment to the nucleus of primary B lymphocytes","volume":"80","author":"Feederle","year":"2006","journal-title":"J Virol"},{"key":"10.1016\/j.semcancer.2008.09.001_bib27","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1128\/JVI.02227-07","article-title":"Standardized and highly efficient expansion of Epstein-Barr virus-specific CD4+ T cells by using virus-like particles","volume":"82","author":"Adhikary","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.semcancer.2008.09.001_bib28","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1128\/JVI.73.4.2974-2982.1999","article-title":"Genetic evidence that EBNA-1 is needed for efficient, stable latent infection by Epstein-Barr virus","volume":"73","author":"Lee","year":"1999","journal-title":"J Virol"},{"key":"10.1016\/j.semcancer.2008.09.001_bib29","doi-asserted-by":"crossref","first-page":"10989","DOI":"10.1073\/pnas.1832776100","article-title":"The EBV nuclear antigen 1 (EBNA1) enhances B cell immortalization several thousandfold","volume":"100","author":"Humme","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.semcancer.2008.09.001_bib30","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1002\/eji.200324794","article-title":"Epstein-Barr virus nuclear antigen 1 evades direct immune recognition by CD4+ T helper cells","volume":"34","author":"Mautner","year":"2004","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.semcancer.2008.09.001_bib31","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1084\/jem.20040121","article-title":"CD8 T cell recognition of endogenously expressed Epstein-Barr virus nuclear antigen 1","volume":"199","author":"Lee","year":"2004","journal-title":"J Exp Med"},{"key":"10.1016\/j.semcancer.2008.09.001_bib32","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1084\/jem.20062508","article-title":"Influence of translation efficiency of homologous viral proteins on the endogenous presentation of CD8+ T cell epitopes","volume":"204","author":"Tellam","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.semcancer.2008.09.001_bib33","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1084\/jem.20041542","article-title":"CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells","volume":"201","author":"Pudney","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.semcancer.2008.09.001_bib34","doi-asserted-by":"crossref","first-page":"7641","DOI":"10.1128\/JVI.79.12.7641-7647.2005","article-title":"Defective infectious particles and rare packaged genomes produced by cells carrying terminal-repeat-negative Epstein-Barr virus","volume":"79","author":"Feederle","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.semcancer.2008.09.001_bib35","doi-asserted-by":"crossref","first-page":"7825","DOI":"10.1128\/JVI.00445-07","article-title":"Epstein-Barr virus entry","volume":"81","author":"Hutt-Fletcher","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.semcancer.2008.09.001_bib36","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/523813","article-title":"Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults","volume":"196","author":"Sokal","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.semcancer.2008.09.001_bib37","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1016\/j.vaccine.2007.04.008","article-title":"Phase I\/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults","volume":"25","author":"Moutschen","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.semcancer.2008.09.001_bib38","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1586\/14760584.5.2.295","article-title":"Successes and remaining challenges after 10 years of varicella vaccination in the USA","volume":"5","author":"Davis","year":"2006","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.semcancer.2008.09.001_bib39","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S0140-6736(06)69561-5","article-title":"Varicella","volume":"368","author":"Heininger","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.semcancer.2008.09.001_bib40","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1002\/j.1460-2075.1996.tb00674.x","article-title":"Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice","volume":"15","author":"Wilson","year":"1996","journal-title":"EMBO J"},{"key":"10.1016\/j.semcancer.2008.09.001_bib41","doi-asserted-by":"crossref","first-page":"14269","DOI":"10.1073\/pnas.2336099100","article-title":"Epstein-Barr virus provides a survival factor to Burkitt\u2019s lymphomas","volume":"100","author":"Kennedy","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.semcancer.2008.09.001_bib42","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.1128\/JVI.02596-07","article-title":"Epstein-Barr virus nuclear antigen 1 does not cause lymphoma in C57BL\/6J mice","volume":"82","author":"Kang","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.semcancer.2008.09.001_bib43","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1073\/pnas.0408774102","article-title":"Epstein-Barr virus nuclear antigen 1 does not induce lymphoma in transgenic FVB mice","volume":"102","author":"Kang","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.semcancer.2008.09.001_bib44","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1586\/14760584.6.3.381","article-title":"Virus-like particles: flexible platforms for vaccine development","volume":"6","author":"Chackerian","year":"2007","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.semcancer.2008.09.001_bib45","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1517\/14712598.7.7.997","article-title":"Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer","volume":"7","author":"Ramqvist","year":"2007","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.semcancer.2008.09.001_bib46","doi-asserted-by":"crossref","first-page":"4924","DOI":"10.1128\/JVI.69.8.4924-4932.1995","article-title":"PREPs: herpes simplex virus type 1-specific particles produced by infected cells when viral DNA replication is blocked","volume":"69","author":"Dargan","year":"1995","journal-title":"J Virol"},{"key":"10.1016\/j.semcancer.2008.09.001_bib47","series-title":"Fields virology","first-page":"2701","article-title":"Cytomegaloviruses","author":"Mocarski","year":"2007"},{"key":"10.1016\/j.semcancer.2008.09.001_bib48","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1128\/JVI.79.2.841-852.2005","article-title":"Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class II immune evasion","volume":"79","author":"Ressing","year":"2005","journal-title":"J Virol"},{"key":"10.1016\/j.semcancer.2008.09.001_bib49","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1073\/pnas.0611128104","article-title":"Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion","volume":"104","author":"Rowe","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.semcancer.2008.09.001_bib50","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1128\/JVI.01946-07","article-title":"The DNase of gammaherpesviruses impairs recognition by virus-specific CD8+ T cells through an additional host shutoff function","volume":"82","author":"Zuo","year":"2008","journal-title":"J Virol"}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X08000746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X08000746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T19:21:21Z","timestamp":1588965681000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X08000746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S1044579X08000746"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2008.09.001","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}